Oruka Therapeutics has been selected to join the Nasdaq Biotechnology Index (NBI). This prestigious inclusion highlights the company’s growing presence in the biotechnology industry. The NBI is a widely recognized index that tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq stock exchange. Oruka Therapeutics’ addition to the index is a reflection of its commitment to innovation and excellence in the field of biotechnology. This recognition will further enhance the company’s visibility among investors and industry stakeholders. Joining the NBI is a significant milestone for Oruka Therapeutics as it continues to make strides in advancing healthcare through groundbreaking research and development.